Request Proposal
Full-Service Clinical Research Organization

The Fastest Path from Protocol to Patient in South Asia

Partner with a full-service CRO delivering faster patient recruitment, rigorous regulatory compliance, and submission-ready clinical data across Pakistan — without ever trading away compliance or data integrity.

Start a Conversation → Submit an RFP → Our Services
✓ ICH-GCP Aligned
✓ DRAP Expertise
✓ Phase I–IV Support
240M+ Potential patient population across Pakistan
Global Standards. Local expertise built for sponsor-grade execution.
Clinical Advantage

Why Conduct Clinical Trials in Pakistan?

Pakistan is rapidly becoming a preferred global hub for clinical development. ViSole Pakistan helps international pharmaceutical companies leverage these regional strengths to accelerate drug-development timelines.

✚

Massive Patient Access

Direct connection to a population of over 240 million with centralized hospitals, making patient recruitment incredibly fast.

⚕

Expert Medical Doctors

Collaborations with top-tier, English-speaking medical investigators trained in international research standards.

$

Cost-Effective Operations

High-quality data and trial execution at a fraction of Western operational cost.

⌁

Treatment-Naïve Patients

Access to patients who have not yet received advanced therapies, supporting clean and highly reliable clinical data.

Nationwide Research Network

Connecting Sponsors to Clinical Trial Units Across Pakistan

Our local network helps sponsors identify qualified, high-recruitment research sites and experienced investigators across key cities and therapeutic areas.

✓ Pre-vetted investigator sites
✓ Centralized tertiary hospitals
✓ Therapeutic-area expertise
✓ Backup site planning
Our Track Record

Numbers That Matter to Sponsors

The metrics global pharmaceutical and biotechnology companies evaluate when choosing a regional clinical research partner.

00+ Clinical Trials Supported Across Phase I–IV
00+ Active Clinical Trial Units
00+ Patients Recruited to Date
00+ Therapeutic Areas
100% ICH-GCP & DRAP-Compliant Study Conduct
End-to-End Research Solutions

Everything Your Trial Needs Under One Experienced Team

From regulatory submission and site initiation to recruitment, monitoring, safety surveillance and final data delivery.

01

Clinical Trial Management

End-to-end oversight of Phase I–IV human trials, ensuring timely, cost-effective and compliant study execution.

↗
02

Regulatory Affairs

Expert handling of approvals with the Drug Regulatory Authority of Pakistan and relevant ethics committees.

↗
03

Site Monitoring

Rigorous on-site monitoring focused on protocol compliance, data integrity and patient safety.

↗
04

Pharmacovigilance & Safety Monitoring

Round-the-clock adverse event surveillance and expedited safety reporting to keep every study audit-ready.

↗
05

Biometrics & Data Management

Transform clinical trial data into high-quality, regulatory submission-ready evidence through expert data management and biostatistical analysis.

↗
06

Patient Recruitment & Retention

Accelerating enrollment with targeted recruitment strategies and proven patient-retention programs.

↗
Quality & Compliance

Global Research Standards. Ground-Level Execution.

Every ViSole Pakistan study is managed around internationally recognized clinical-research standards, rigorous source-data verification and sponsor-ready documentation.

ICH-GCP Good Clinical Practice aligned operations
DRAP Local regulatory navigation and submission expertise
Patient Safety Ethical conduct and safety-first study execution
Audit Ready Traceable, sponsor-ready clinical documentation
Frequently Asked Questions

What Sponsors Usually Want to Know

Practical answers about recruitment, regulatory timelines, trial quality, feasibility and sponsor engagement.

Pakistan offers a combination of a very large, treatment-naïve patient population and a centralized hospital network, enabling rapid recruitment. International sponsors can also benefit from experienced English-speaking investigators and competitive operational costs.
Clinical trial approvals are governed by DRAP. Timelines vary according to trial phase and therapeutic complexity, but regulatory and ethical approvals typically take approximately 8–12 weeks from submission.
Clinical operations follow ICH-GCP guidelines, the Declaration of Helsinki and applicable local regulations. Regular monitoring and source-data verification support reliable, audit-ready data.
Core therapeutic experience includes Oncology, Cardiology, Diabetology and Metabolic Disorders, Infectious Diseases, Gastroenterology and Pediatrics, supported by a network of leading medical institutions.
Using an existing network of pre-vetted investigator sites, local protocol feasibility assessments and patient-population estimates can typically be delivered within 5–7 business days after receiving the core protocol layout.
Yes. Sponsors can work with ViSole through full-service CRO engagements, functional service provider models or staff augmentation depending on the study's needs.
Trial data, study results and intellectual property generated during the engagement remain the property of the sponsor according to the applicable Clinical Trial Agreement.
Yes. Sponsor audits and regulatory inspections are supported as part of normal clinical operations, including preparation of audit-ready trial master files and CAPA support where required.